The concept of &dquo;endocrine disruptors&dquo; in our environment has received considerable public and scientific attention in the last few years, and it is not necessary here to cover the already well-worked aspects of this discussion. What does remain interesting is the lack of progress in several areas. There is still much discussion over some very basic issues, such as the definition of an &dquo;endocrine disruptor&dquo; (1) . The original concern arose over reports that a range of wildlife and human reproductive abnormalities are on the increase (eg, declining sperm counts, hypospadias, and breast cancer in humans). The scientific debate has spread from the original focus on estrogen and androgen receptor agonists/antagonists to encompass broader aspects, such as the immune and neuroendocrine systems. However, there is still a need for studies to better define the reality and nature of the hazards posed and to progress understanding of the originally perceived problem of exposure of wildlife and humans to estrogen-androgen receptor agonists/antagonists. A definitive cause-and-effect link has yet to be established, despite the fact that a wide range of chemical classes have been associated with this phenomenon. No new chemical classes have been added to the lists of alleged &dquo;endocrine disruptors&dquo; in the last 2 years. Primarily, public concern and the development of the testing guidelines by the US Environmental Protection Agency (US EPA) are driving the issue of endocrine disruptors. The US Congress instructed that a testing strategy for endocrine disruptors should be implemented by August 1999 (3). This strategy will include in vitro/in vivo assays to assess the potential of a chemical for estrogen, androgen, and thyroid activity. Very few of these assays have undergone a &dquo;validation&dquo; process or been assessed against defined endocrine endpoints. The main problem is that there is an absence of reference chemicals for human or rodent toxic endpoints, apart from diethylstilbestrol (4). It is crucial that any assay purporting to reflect an endocrine endpoint has the following characteristics: it is predictive, the technology is transferable, it is metabolically competent, it is short term, and it has undergone an appropriate validation process.
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One of the estrogenic assays being considered as part of a short-term in vivo screen is the uterotrophic assay, which has been widely used for many years as the assay of choice for assessment of pharmaceutical agents (8) . In this mode, it has been used to assess the relative potency of &dquo;active&dquo; moieties, and now it has been given a new lease on life in terms of its use in the assessment of weakly active estrogens (6) . This assay provides a useful example of an outwardly simple assay that can have many variations in terms of protocol design. For instance, the dose selection should be thought through to ensure that the highest dose is of biological relevance and unlikely to elicit adverse toxicity that could have secondary effects on the endocrine system. This is a different approach to that normally employed in dose setting in a routine toxicity study. Consideration should be given to the interpretation of a linear vs a nonlinear dose-response curve, and of course, the dose route should be based on the bioavailability and the route of exposure.
It would not appear to be an issue as to whether ovariectomized or immature rats are used; this is simply a means of quenching the endogenous estrogen. Perhaps the extra cost of an ovariectomized animal can be a factor. However, if immature rats are used, it is absolutely crucial to ensure that the rats are put onto the test in the right time window of 22-23 days of age. The endogenous estrogen levels rise about 4-5 days later and could give spurious results. The endpoint of this assay is simplemeasurement of uterine weight. Therefore, the accuracy of the dissection technique is very important. The uteri in the immature rat are very small and threadlike, and the response we may be looking for with the &dquo;weak&dquo; estrogens is likely to be marginal, so any minor perturbation in the accuracy of dissection could have significant implications. I am laboring over these points to stress the importance of rigor in our approach to what may outwardly appear to be an easy, straightforward methodology. This philosophy is equally appropriate to many of the other assays being considered for assessment of potential endocrine disruptors. Having made these points, perhaps it is more apparent that there is a need to validate assays against a so-called weak estrogen, such as the phytoestrogen coumestrol, to ensure that they have the appropriate level of sensitivity. Attention should also be paid to the choice of dosing vehicle and diet in order to ensure that there is no residual estrogenic activity as a result of the phytoestrogen content.
The need for standardization of protocols that can yield reproducible results across many laboratories is paramount (2) . If assays are to be conducted in laboratories with no research background in the area in which the pitfalls are known, there is a need for robustness in the protocols. Realistically, in the complex area of endocrine activity, it will be essential to carry out a battery of assays covering multiple endpoints in order to give a true reflection of the potential of a chemical for endocrine activity.
A cautionary, pragmatic approach is required to deal with the avalanche of data being generated in this field. Particular attention should be paid to scientific rigor, and care should be taken that we do not overinterpret data. For example, the result of an in vitro assay must be interpreted with caution as an indication of the potential for a chemical to have endocrine activity and should not be used for risk assessment. We need to look at the kind of information that is acquired from an in vitro assay and decide how it can be used. For instance, does binding to a receptor necessarily indicate the potential for an adverse biological event? It is common to use in vitro data to rank chemicals in terms of their potencies. In the area of endocrine disruptors, the majority of implicated chemicals appear to be weakly active at the relevant receptor, compared to estradiol or diethylstilbestrol. Therefore, it becomes a game of ranking weakly active chemicals based on information from assays that still await standardization, an exercise which is of doubtful value.
Furthermore, an in vitro result should be confirmed in vivo because of the need to address critical time points in development, interaction with serum-binding globulins, and metabolism. An increase in the level of histopathologic assessment is now required by regulatory guidelines in some reproductive toxicology studies, including the counting of ovarian follicles and corpora lutea. It is essential to review all of the results generated within these complex studies to ensure correct interpretation (ie, use a weight-of-evidence approach). The tiered approach to testing for endocrine disruptors appears to have gained general consent, and there have been several publications on this topic (5, 7) . This would appear to be the most practical approach so long as the data from each tier are used appropriately. The first tier that is acquiring favor is an in vitro screen that looks at activity at the estrogen receptors a and 13, at the androgen receptor, and at the thyroid receptor, with and without metabolic activation. This screen can identify the potential of a chemical to have endocrine-disrupting activity, but this information should not be regarded as information that is appropriate for the assessment of either hazard or risk. The next level involves the use of in vivo shortterm assays, such as that described above (ie, the uterotrophic assay). This kind of assay may provide more of an indication of the potential hazard, but it does not provide an indication of the biological relevance or risk. To make a realistic judgment regarding risk assessment, consideration has to be given to running a multigeneration study. This should be combined with exposure data to ensure that an accurate risk assessment can be carried out.
Unfortunately, we then have to address the complex multifactorial exposure paradigm for endocrine disruptors. We must remember that &dquo;endocrine disruptors&dquo; are dose-, age-, and species-dependent. This has led to the need to query the relevance of traditional methods of risk assessment because of the differences in metabolism and potency that occur between species. Biodegradability and persistence in the environment are, of course, factors to be considered, particularly in the context of the alleged effects in wildlife that are attributable to endocrine disruptors. Knowledge of the bioavailability via the most appropriate route of exposure is important, and exposure may be via more than one route. Of more specific relevance to endocrine disruptors is an awareness of whether exposure is likely to occur during critical periods, such as during testicular development. There may be a latent period before any adverse effects would likely to become manifest. All this makes the exposure paradigm for endocrine disruptors particularly onerous and the ability to relate cause and effect extremely difficult.
To summarize, it is evident that a vast amount of data will be generated in the area of endocrine-disruptor testing, and hopefully some light will dawn. But inevitably this will only serve to increase the complexity of the science in an already complicated area. So the need for scientific rigor is key, and repeatability of results is crucial, as is standardization of protocols to assist in the consistency of results obtained across a wide range of laboratories.
From a pathologist's perspective, 4 main areas are paramount, namely (a) knowledge of the disease process of concern in wildlife or human populations, (b) an understanding of mechanisms, (c) clear identification of appropriate endocrine endpoints, and (d) identification of true reference chemicals. It is a complex issue requiring a meeting of minds and a sharing of data to move our understanding forward.
